Algert Global LLC Acquires Shares of 12,791 Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Algert Global LLC purchased a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 12,791 shares of the biopharmaceutical company’s stock, valued at approximately $670,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Vanguard Group Inc. lifted its stake in shares of Halozyme Therapeutics by 1.2% during the 4th quarter. Vanguard Group Inc. now owns 13,259,514 shares of the biopharmaceutical company’s stock worth $490,072,000 after purchasing an additional 152,870 shares during the last quarter. TD Asset Management Inc boosted its stake in Halozyme Therapeutics by 28.1% in the first quarter. TD Asset Management Inc now owns 2,541,266 shares of the biopharmaceutical company’s stock valued at $103,379,000 after acquiring an additional 557,350 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in Halozyme Therapeutics by 12.4% in the second quarter. Dimensional Fund Advisors LP now owns 1,897,759 shares of the biopharmaceutical company’s stock worth $99,363,000 after purchasing an additional 209,530 shares during the last quarter. Epoch Investment Partners Inc. increased its position in shares of Halozyme Therapeutics by 23.3% during the first quarter. Epoch Investment Partners Inc. now owns 1,433,612 shares of the biopharmaceutical company’s stock worth $58,319,000 after purchasing an additional 270,579 shares in the last quarter. Finally, American Century Companies Inc. lifted its holdings in shares of Halozyme Therapeutics by 9.7% during the 2nd quarter. American Century Companies Inc. now owns 821,266 shares of the biopharmaceutical company’s stock valued at $43,002,000 after purchasing an additional 72,544 shares during the last quarter. 97.79% of the stock is owned by institutional investors.

Insider Activity

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of the business’s stock in a transaction on Wednesday, September 18th. The stock was sold at an average price of $62.03, for a total transaction of $620,300.00. Following the transaction, the senior vice president now owns 173,756 shares of the company’s stock, valued at approximately $10,778,084.68. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, CFO Nicole Labrosse sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, July 22nd. The stock was sold at an average price of $53.93, for a total value of $269,650.00. Following the transaction, the chief financial officer now directly owns 15,480 shares in the company, valued at approximately $834,836.40. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Michael J. Labarre sold 10,000 shares of the stock in a transaction that occurred on Wednesday, September 18th. The stock was sold at an average price of $62.03, for a total value of $620,300.00. Following the completion of the transaction, the senior vice president now owns 173,756 shares of the company’s stock, valued at $10,778,084.68. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 84,881 shares of company stock worth $4,932,284 over the last quarter. 2.40% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

HALO has been the topic of several recent analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $65.00 target price on shares of Halozyme Therapeutics in a research report on Friday. TD Cowen upped their price objective on shares of Halozyme Therapeutics from $59.00 to $65.00 and gave the company a “buy” rating in a report on Wednesday, August 7th. Benchmark reaffirmed a “buy” rating and issued a $60.00 price objective on shares of Halozyme Therapeutics in a research report on Thursday, August 8th. JPMorgan Chase & Co. downgraded shares of Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and boosted their target price for the stock from $52.00 to $57.00 in a research report on Thursday, September 19th. Finally, Morgan Stanley raised their price target on shares of Halozyme Therapeutics from $59.00 to $64.00 and gave the stock an “overweight” rating in a report on Wednesday, August 7th. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $60.00.

Halozyme Therapeutics Trading Down 2.1 %

Shares of Halozyme Therapeutics stock opened at $59.18 on Friday. The stock has a market cap of $7.53 billion, a PE ratio of 24.45, a price-to-earnings-growth ratio of 0.56 and a beta of 1.27. The firm has a fifty day moving average price of $58.96 and a 200 day moving average price of $50.35. Halozyme Therapeutics, Inc. has a 1 year low of $32.83 and a 1 year high of $65.53. The company has a debt-to-equity ratio of 5.19, a current ratio of 7.41 and a quick ratio of 6.21.

Halozyme Therapeutics (NASDAQ:HALO) last posted its earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.91 earnings per share for the quarter, beating the consensus estimate of $0.73 by $0.18. The firm had revenue of $231.40 million during the quarter, compared to analyst estimates of $204.94 million. Halozyme Therapeutics had a net margin of 38.62% and a return on equity of 195.80%. The business’s quarterly revenue was up 4.7% on a year-over-year basis. During the same period in the previous year, the firm earned $0.68 EPS. Equities research analysts predict that Halozyme Therapeutics, Inc. will post 3.71 earnings per share for the current year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.